Yun‐Gyoo Lee

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee et al. · Journal of Clinical Oncology · 2017 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Sehhoon Park, Tae Min Kim, Ji‐Youn Han et al. · Journal of Clinical Oncology · 2023 · 164 citations · Full text

Medicine, Oncology, Pharmacology +17

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee et al. · The Lancet Oncology · 2019 · 135 citations

Medicine, Oncology, Pharmacology +17

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Byoung Chul Cho, Ji‐Youn Han, Sang‐We Kim et al. · Journal of Thoracic Oncology · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +13